Last updated on June 2012

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

---

Brief description of study

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

Detailed Study Description

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01371981?term=AAML1031&rank=1